JBIO

Jade Biosciences, Inc.
—

Company Information

Company Name
Jade Biosciences, Inc.
CIK
CIK0001798749
Category
<br>Emerging growth company
Ticker: Exchange
JBIO: Nasdaq
Fiscal Year End
December 31
Owner Organization
03 Life Sciences
SIC
2834
SIC Description
Pharmaceutical Preparations
Ticker
JBIO

SEC filing data through

Insider Sentiment

Last purchase
2025-05-16
Last sale
2024-06-14
Shares purchased (TTM)
934,110
Shares sold (TTM)
45,600
Buy ratio (TTM)95.3%

Institutional Sentiment

As of
2026-06-30
Institutional shares owned
72,709,700
Shares outstanding
61,050,775
Ownership
119.10%
+9.13% Y/Y

Earnings Market Reaction

Filing date
2026-11-13
Price on filing date
—
1-month reaction
Pending
3-month reaction
Pending
Drift continued5/11 (45%)
Faded / reversed6/11 (55%)

Balance Sheet

Values in millions ($)
Line item2026-09-302026-06-302026-03-312025-12-312025-09-302025-06-302025-03-312024-12-312024-09-302024-06-302024-03-312023-12-31Subscriber-only columnSubscriber-only columnSubscriber-only columnSubscriber-only columnSubscriber-only columnTrend
Series Seed Convertible Preferred Stock---00-000020--
Series A Non Voting Convertible Preferred Stock-00000-0----
Assets Current
Cash And Cash Equivalents At Carrying Value8010755885022144693131923
Short Term Investments395354256248149-32058739099
Prepaid Expense And Other Assets Current101071322102742
Assets Current486471319349201223777091111103124
Property Plant And Equipment Net000000000000
Operating Lease Right Of Use Asset111111000111
Other Assets Noncurrent000000-30032
Assets486472319350202224787391112107127
Liabilities Current
Operating Lease Liability Current------000000
Accounts Payable Current374218011432
Liabilities Current30322217222221210171618
Other Liabilities------000000
Operating Lease Liability Noncurrent111111-00000
Liabilities313223172322212010171618
Preferred Stock Value----00------
Stockholders Equity
Common Stock Value000000000000
Additional Paid In Capital7637115125073223193110308306278273
Accumulated Other Comprehensive Income Loss Net Of Tax-2-1-000-0000-0-00
Retained Earnings Accumulated Deficit-306-271-215-174-142-117-236-47-228-211-187-163
Stockholders Equity456440296333179202-84-47-17-091109
Liabilities And Stockholders Equity486472319350202224787391112107127
Preferred Stock Par Or Stated Value Per Share------0.000.000.000.000.000.00
Related Party-000-22-0----
Preferred Stock Shares Authorized----1313101010101010
Preferred Stock Shares Issued----00000000
Preferred Stock Shares Outstanding----00000000
Common Stock Par Or Stated Value Per Share0.000.000.000.000.000.000.000.000.000.000.000.00
Common Stock Shares Authorized30030030030030030015040150150150150
Common Stock Shares Issued67644949333329429292828
Shares Outstanding67644949333329429292828
Convertible Long Term Notes Payable---00--108----

Select a line item above to chart it.

Recent filings

Financial statements beyond 3 years are for subscribers only.

Unlock 17+ years of income statements, balance sheets, and cash flow statements

Start 7-day free trial

Jade Biosciences, Inc. (JBIO) — SEC Financial Statements & Analysis

Jade Biosciences, Inc. (JBIO) is a pharmaceutical preparations company, incorporated in DE. Jade Biosciences, Inc. trades on Nasdaq as: JBIO. Jade Biosciences, Inc. (JBIO)'s most recent SEC filing is a Form 10-Q for the period ended 2026-09-30, filed with the SEC on 2026-11-13. Based on that filing, Jade Biosciences, Inc. carries a market cap of $1.01B, a P/E ratio of -6.18x, a P/B ratio of 2.21x, an enterprise value of $927.89M, and an EV/EBITDA multiple of -5.24x. On profitability, it posts a Return on Equity (ROE) of -51.39%, a Return on Assets (ROA) of -47.36%, and a Return on Invested Capital (ROIC) of -70.14%. Per share, it reports EPS of $-2.27, diluted EPS of $-2.27, free cash flow per share of $-1.82, and a dividend per share of $0.00. Over the trailing year, it posted net income growth of 60.21% year-over-year and EPS growth of -11.63% year-over-year. On the balance sheet, it maintains a current ratio of 16.03x, a quick ratio of 15.70x, working capital of $455.27M, a debt-to-equity ratio of 0.07x, a debt ratio of 0.06, an interest coverage ratio of -12.60x, free cash flow of $-130.30M (TTM), and net debt of $-80.39M. Figures sourced from SEC EDGAR.

Market Cap
$1.01B
P/E TTM
-6.18x
EPS TTM
$-2.27
P/B TTM
2.21x
ROE TTM
-51.39%
ROA TTM
-47.36%
Debt To Equity
0.07x
Free Cash Flow TTM
$-130.30M

Data as of 2026-09-30 · Source: SEC EDGAR

Frequently Asked Questions

What industry is Jade Biosciences, Inc. in?

Jade Biosciences, Inc. (JBIO) operates in the Pharmaceutical Preparations industry.

What exchange does JBIO trade on?

Jade Biosciences, Inc. (JBIO) trades on the Nasdaq.

Where is Jade Biosciences, Inc. incorporated?

Jade Biosciences, Inc. is incorporated in DE.

When was Jade Biosciences, Inc. (JBIO)'s most recent SEC filing?

Jade Biosciences, Inc. (JBIO)'s most recent SEC filing is a Form 10-Q for the period ended 2026-09-30, filed with the SEC on 2026-11-13.

What is JBIO's market cap?

Jade Biosciences, Inc. (JBIO) has a market capitalization of $1.01B as of 2026-09-30.

What is JBIO's EPS (earnings per share)?

Jade Biosciences, Inc. (JBIO)'s trailing twelve month EPS is $-2.27 as of 2026-09-30.

What is JBIO's ROE (return on equity)?

Jade Biosciences, Inc. (JBIO)'s trailing twelve month Return on Equity (ROE) is -51.39% as of 2026-09-30.

What is JBIO's ROA (return on assets)?

Jade Biosciences, Inc. (JBIO)'s trailing twelve month Return on Assets (ROA) is -47.36% as of 2026-09-30.

What is JBIO's ROIC (return on invested capital)?

Jade Biosciences, Inc. (JBIO)'s trailing twelve month Return on Invested Capital (ROIC) is -70.14% as of 2026-09-30.

What is JBIO's EV/EBITDA?

Jade Biosciences, Inc. (JBIO)'s trailing twelve month EV/EBITDA is -5.24x as of 2026-09-30.

Wall Street's data.
Main Street's price.